89 related articles for article (PubMed ID: 38504095)
1. Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children.
Dinh JC; Pearce RE; Van Haandel L; Gaedigk A; Leeder JS
Drug Metab Dispos; 2016 Jul; 44(7):1070-9. PubMed ID: 27052878
[TBL] [Abstract][Full Text] [Related]
2. Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis.
Liao Y; Sun Y; Guo J; Kang Z; Sun Y; Zhang Y; He J; Huang C; Sun X; Zhang JM; Wang J; Wang HN; Chen ZY; Wang K; Pan J; Ni AH; Weng S; Wang A; Cao C; Sun L; Zhang Y; Kuang L; Zhang Y; Liu Z; Yue W;
EBioMedicine; 2024 Jun; 104():105165. PubMed ID: 38776596
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2D6 genetic variation on patient-reported symptom improvement and side effects among children and adolescents treated with amphetamines.
Gerlach S; Maruf AA; Shaheen SM; McCloud R; Heintz M; McAusland L; Arnold PD; Bousman CA
Pharmacogenet Genomics; 2024 Jul; 34(5):149-153. PubMed ID: 38517706
[TBL] [Abstract][Full Text] [Related]
4. Atomoxetine: toxicological aspects of a new treatment for Attention Deficit Hyperactivity Disorder in Brazil.
Morais GCF; Akash S; da Silva ED; de Oliveira CBS; Rodrigues-Neto JF; Fulco UL; Akter S; Oliveira JIN
Trends Psychiatry Psychother; 2024 Jun; ():. PubMed ID: 38830052
[TBL] [Abstract][Full Text] [Related]
5. Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together.
Guo HL; Wu DD; Fu D; Li Y; Wang J; Zhang YY; Wang WJ; Huang J; Fang WR; Xu J; Hu YH; Liu QQ; Chen F
Transl Psychiatry; 2024 Mar; 14(1):151. PubMed ID: 38504095
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
[TBL] [Abstract][Full Text] [Related]
7. [A precision medication study of atomoxetine in children with attention deficit hyperactivity disorder:
Fu D; Guo HL; Hu YH; Chen F
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jan; 25(1):98-103. PubMed ID: 36655671
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.
Brown JT; Bishop JR
Pharmacogenomics; 2015; 16(13):1513-20. PubMed ID: 26314574
[TBL] [Abstract][Full Text] [Related]
10. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.
Brown JT; Abdel-Rahman SM; van Haandel L; Gaedigk A; Lin YS; Leeder JS
Clin Pharmacol Ther; 2016 Jun; 99(6):642-50. PubMed ID: 26660002
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data.
Smith RL; Molden E; Bernard JP
Br J Clin Pharmacol; 2023 Jul; 89(7):2246-2253. PubMed ID: 36851891
[TBL] [Abstract][Full Text] [Related]
12. Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence.
Fu D; Guo HL; Hu YH; Fang WR; Liu QQ; Xu J; Wu DD; Chen F
Eur J Clin Pharmacol; 2023 Mar; 79(3):349-370. PubMed ID: 36645468
[TBL] [Abstract][Full Text] [Related]
13. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate.
Nijenhuis M; Soree B; Jama WOM; de Boer-Veger NJ; Buunk AM; Guchelaar HJ; Houwink EJF; Rongen GA; van Schaik RHN; Swen JJ; Touw D; van der Weide J; van Westrhenen R; Deneer VHM; Risselada A
Eur J Hum Genet; 2023 Dec; 31(12):1364-1370. PubMed ID: 36509836
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
